IP Library › Granted Patent US 7,034,005
Granted Patent B2
US 7,034,005 · App. 10/294,587 · Granted Apr 25, 2006

Use of agent for suppressing infection and proliferation of human immunodeficiency syndrome virus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,034,005
App. No.
10/294,587
Granted
Apr 25, 2006
Kind
B2
Abstract

The present invention relates to agent for suppressing infection and proliferation of human immunodeficiency syndrome virus (HIV-1), which infects immunocompetent cells such as macrophage or dendritic cell and causes destruction of immune system, and use of known compounds, macrolide derivatives for suppression of infection and proliferation of human immunodeficiency syndrome virus in M type macrophage derived from human monocytes. The present invention is useful for treatment of patients with HIV-1 infection by low cost chemotherapeutic agents, and in addition, is clinically used as supplement agent in HAART.

Claims (10)

1. A method for suppressing infection and/or proliferation of human immunodeficiency syndrome virus in a macrophage derived from a human monocyte, comprising treating said macrophage with an effective amount of a macrolide derivative, wherein the macrolide derivatives is 11-(1′-hydroxypropyl)-3-[2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl]oxy]-5-[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2,4,6,8,11,14-hexamethyl-10,13-15-tri-oxatricyclo[9.2.1.1. 9.6 ]-pentadecane-1-one or 4,13-Dioxabicyclo[8.2.1]tridec-12-en-5-one, 7-[(2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl)oxy]-3-(1,2-dihydroxy-1-methylbutyl)-2,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy], and wherein the macrophage derived from human monocytes is an M type macrophage.

2. A method for suppressing infection and/or proliferation of human immunodeficiency syndrome virus in a macrophage derived from a human monocyte, comprising treating said macrophage with an effective amount of a macrolide derivative, wherein the macrolide derivatives is 11-(1′-hydroxypropyl)-3-[2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl]oxy]-5-[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2,4,6,8,11,14-hexamethyl-10,13-15-tri-oxatricyclo[9.2.1.1. 9.6 ]-pentadecane-1-one or 4,13-Dioxabicyclo[8.2.1]tridec-12-en-5-one, 7-[(2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl)oxy]-3-(1,2-dihydroxy-1-methylbutyl)-2,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy], and wherein the macrolide derivative suppresses the proliferation of the virus by suppressing expression of tyrosine kinase Hck protein and activation of p38MAPK in an M type M macrophage.

3. A method for suppressing infection and/or proliferation of human immunodeficiency syndrome virus in a macrophage derived from a human monocyte, comprising treating said macrophage with an effective amount of a macrolide derivative, wherein the macrolide derivatives is 11-(1′-hydroxypropyl)-3-[2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl]oxy]-5-[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2,4,6,8,11,14-hexamethyl-10,13-15-tri-oxatricyclo[9.2.1.1. 9.6 ]-pentadecane-1-one or 4,13-Dioxabicyclo[8.2.1]tridec-12-en-5-one, 7-[(2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl)oxy]-3-(1,2-dihydroxy-1-methylbutyl)-2,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy], and wherein said macrophage is in vitro.

4. The method according to claim 3 , wherein the macrolide derivative suppresses the proliferation of the virus by suppressing expression of tyrosine kinase Hck protein and activation of p38MAPK in M type M macrophage.

5. The method according to claim 3 , wherein the macrophage derived from human monocytes is an M type M macrophage.

6. The method according to claim 3 , wherein the macrolide derivative suppresses the proliferation of the virus by suppressing expression of tyrosine kinase Hck protein and activation of p38MAPK in M type N macrophage.

7. A method for suppressing infection and/or proliferation of human immunodeficiency syndrome virus in a macrophage derived from a human monocyte, comprising treating said macrophage with an effective amount of a macrolide derivative, wherein the macrolide derivatives is 11-(1′-hydroxypropyl)-3-[2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl]oxy]-5-[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2,4,6,8,11,14-hexamethyl-10,13-15-tri-oxatricyclo[9.2.1.1. 9.6 ]-pentadecane-1-one (EM201) , or 4,13-Dioxabicyclo[8.2.1]tridec-12-en-5-one, 7-[(2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl)oxy]-3-(1,2-dihydroxy-1-methylbutyl)-2,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-dimethylamino)-β-D-xylo-hexopyranosyl]oxy] (EM703).

8. The method according to claim 7 , wherein said macrolide derivative is 11-(1′-hydroxypropyl)-3-[2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl]oxy]-5-[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl)oxy]-2,4,6,8,11,14-hexamethyl-10,13-15-tri-oxatricyclo[9.2.1.1. 9.6 ]-pentadecane-1-one (EM201).

9. The method according to claim 7 , wherein said macrolide derivative is 4,13-Dioxabicyclo[8.2.1]tridec-12-en-5-one, 7-[(2,6-dideoxy-3-C-methyl-α-L-ribo-hexopyranosyl)oxy]-3-(1,2-dihydroxy-1-methylbutyl)-2,6,8,10,12-pentamethyl-9-[[3,4,6-trideoxy-3-dimethylamino)-β-D-xylo-hexopyranosyl]oxy](EM703).

10. The method according to claim 7 , wherein said macrophage is in vitro.